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Abstract
Alzheimer’s screening tests are commonly used by doctors to diagnose the pa-
tient’s condition and stage as early as possible. Most of these tests are based on
pen-paper interaction and do not embrace the advantages provided by new tech-
nologies. This paper proposes novel Alzheimer’s screening tests based on virtual
environments and game principles using new immersive technologies combined
with advanced Human Computer Interaction (HCI) systems. These new tests
are focused on the immersion of the patient in a virtual room, in order to mislead
and deceive the patient’s mind. In addition, we propose two novel variations
of Turing Test proposed by Alan Turing as a method to detect dementia. As
a result, four tests are introduced demonstrating the wide range of screening
mechanisms that could be designed using virtual environments and game con-
cepts. The proposed tests are focused on the evaluation of memory loss related
to common objects, recent conversations and events; the diagnosis of problems in
expressing and understanding language; the ability to recognise abnormalities;
and to differentiate between virtual worlds and reality, or humans and machines.
The proposed screening tests were evaluated and tested using both patients and
healthy adults in a comparative study with state-of-the-art Alzheimer’s screen-
ing tests. The results show the capacity of the new tests to distinguish healthy
people from Alzheimer’s patients.
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1. Introduction
Dementia is a term used to encompass a number of symptoms such as the
decline of memory, reasoning, language or perceptual interpretation. Specific
combinations of these symptoms are used to define different types of dementia
such as Alzheimer’s or Parkinson’s disease. Alzheimer is a disease that usually
affects elder people, with the number of cases increasing over the last decades.
The number of people with early onset dementia (people under 65 years old) has
also increased in the UK and worldwide [1]. Alzheimer’s is the most common
type; it accounts for 60 to 80 percent of cases, and one of the most noticeable
symptoms is the difficulty in learning new information. In addition, when the
disease advances, there are other symptoms such as disorientation, mood and
behaviour changes; confusion about events, date and place; being suspicious
about family, friends and caregivers; and difficulty in speaking, writing and
walking [2].
According to the World Health Organization, 1.37% of the estimated deaths
around the world in 2030 will be caused by Alzheimer’s disease and other demen-
tias. People with medium dementia live on average 8 years [2]. Currently, when
Alzheimers disease (AD) is diagnosed, the neuronal damage is spread enough to
make it irreversible [3]. When neurons die, the other neurons do not divide and
replace them, as other cells do, so the damage cannot be reversed [2]. Therefore,
it is important to detect dementia at its very early stages in order to reduce the
deterioration speed [4, 5].
The cost of dementia is another issue to take into consideration. The world-
wide cost of dementia is $818 billion, and it will become a trillion by 2018[6].
The cost of dementia in the UK estimated in 2013 was 26.3 billion pounds; 4.3
billions were spent on healthcare costs, of which around 85 millions were spent
on diagnosis [1]. Therefore, it is essential to develop affordable diagnosis and
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support tools, limiting the increasing cost of dementia. One of the proposed
initiatives is focused on the implementation of e-health (the use of Information
Communication Technology (ICT)) solutions to reduce the cost and to make the
health systems and solutions universally accessible [7]. Arief et al presented in
[6] the strengths of e-health tools such as the improvement in accessing health-
care services by senior citizens, their cost-effectiveness and their efficiency in
managing health resources.
Furthermore, Alzheimer’s symptoms are studied to improve the results of
previous approaches or create novel and more accurate methods relying on new
affordable and publicly available technologies. Alzheimer’s detection methods
can be classified in two different categories: invasive and non-invasive. Invasive
methods require obtaining data from the interior of the patient’s body trough
procedures such as lumbar puncture or blood extraction. These tests are not
always safe and comfortable for the patient, while some of them are unbearably
painful. On the other hand, non-invasive tests are harmless and more convenient
during the diagnosis process.
Focusing on non-invasive methods, cognitive test are the most commonly
used Alzheimer tests for diagnosis. These are question/task/problem based
trying to measure patients cognition, while cognition is defined as the use of the
information that has been previously collected by a person to make behavioural
decisions [8]. Cognitive or aptitude tests have high accuracy when it comes to
Alzheimers detection. Nevertheless, one of their weaknesses is the evaluation of
brain’s capacity to compensate brain damage (cognitive reserve) [3, 5]. Another
well-know problem is the adaptability of the tests according to the patient’s IQ,
since most of the tasks that integrate an Alzheimers detection cognitive test
usually are too simple to evaluate intelligent patients. Therefore, it is necessary
to create tests, whose results are not correlated with the IQ of the patients. The
use of computerized tests helps to create intelligence adaptable cognitive tests
[9, 3]. Moreover, based on the available technology, it is possible to design new
types and more effective tests using for example virtual environments (VEs).
Virtual environments provide additional advantages to cognitive tests, since it
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is possible to immerse the patient in a controlled situation [10, 11, 12, 13].
Parsons et al. have demonstrated in [14, 15, 16] the ecological validity of
VEs and their benefits for neurocognitive assessment, such as the precision of
data retrieved by the computer or the better control of the environment. They
also prove the advantages of using virtual reality over the traditional pen and
paper methods.
When it comes to the Alzheimer’s symptoms, the American Psychiatric As-
sociation has gathered in [17] the cognitive domains affected by Alzheimer’s
disease: complex attention, executive function, learning and memory, language,
perceptual-motor and social cognition. The existent tests try to examine spe-
cific cognitive areas. For example, the Mini-Mental State Examination (MMSE)
studied different cognitive areas such as the learning and memory, the complex
attention or the language cognitive domains.
Analysing the cognitive domains affected by Alzheimer’s, a relation can be
found with the areas that Alan Turing uses to define intelligence. Alan Turing
proposed in 1950 a test related with human and computers cognition. It tests
the degree of intelligence of a machine in relation with its ability to impersonate
a human [18]. In order a computer is considered intelligent should posses the
next capabilities [19]: natural language processing, knowledge representation,
automated reasoning and machine learning. Comparing these capabilities with
the correspondent cognitive domains it is possible to consider the use of existent
Turing Test for evaluating human cognition. In addition, according to Warwick
et al [20], the success of Turing test does not depend only in the quality of com-
puter’s AI; it also depends on the intelligence of the human that is judging the
machine. Therefore, reversing this test, it is possible to obtain a cognitive test
that checks the degree of intelligence or the existence of a cognitive impairment.
In this paper, we propose novel cognitive and executive function based, non-
invasive screening tests for early Alzheimers diagnosis implemented as an e-
health tool. These new tests are conducted in a virtual room due to the flexibility
to create different tasks and the capacity of the involved users, [10, 12, 13]. The
developed test has been chosen following the next principles: it should evaluate
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at least one of cognitive domain, it should take advantage of VEs flexibility
and it should be easily upgraded. As a result, an innovative, cost efficient and
flexible e-health Alzheimer’s detection application is introduced.
The remainder of this paper is organized as follows: section 2 describes
previous related work on Alzheimers diagnosis. Section 3 analyses the proposed
methodology and in section 4 details on the evaluation process and the obtained
results are presented. Section 5 gives some conclusion remarks.
2. Previous Work
Apart from the invasive/non-invasive classification, the Alzheimer’s detec-
tion methods can also be classified as non-cognitive and cognitive tests. Cog-
nitive tests encompass the methods that evaluate patients’ cognition and these
procedures are non-invasive and easy to implement. Non-cognitive tests are re-
garded all other methods, invasive or non-invasive, used to detect and diagnose
dementia.
Regarding the non-cognitive approaches, in [2, 21] some of the methods used
to detect dementia are based on defining potential biomarkers that are acquired
through invasive techniques, such as cerebrospinal fluid tau protein and beta-
amyloid peptide. Lau et al proposed in [22] salivary trehalose as a reliable
Alzheimer detector biomarker obtained through non-invasive methods. Those
biomarkers have been proved an accurate indicator of the presence of Alzheimer,
but they are not validated yet in large groups as an accurate and reliable tool
for Alzheimers disease detection, so they cannot be used in medical clinics [2].
There are other non-invasive methods that require the use of external de-
vices during a certain period of time to analyse patients behaviour [? 24]. For
example, Aztiria et al in [24] placed a sensor on the patients foot in order to
analyse their gait (step length and step height), since it reflects patients demen-
tia level. However, the gait measurement method still has some drawbacks, such
as the patient has to wear a device for long periods and the results obtained,
despite being promising, are still not useful, since they have not been tested in
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Alzheimer patients. Abe et al present in [4] another detection method using
sensors in patients’ homes to identify certain events. This non-cognitive ap-
proach is non-invasive and it requires only the consent of the patient to install
the sensors. The main issue with these methods is that the obtained results
are not precise enough (less than 75% detection rates) to provide an accurate
technique for dementia diagnosis at early stages.
Magnetic Resonance Imaging (MRI) is another non-cognitive technique com-
monly used for alzheimer detection that provides accurate results since it is pos-
sible to study visually the deterioration of the brain. In the works presented in
[25, 26] the head MRI data of the patient is compared with the corresponding
data of patients with Alzheimer’s using machine learning techniques. Neverthe-
less, since acquisition of MR images involves the use of medical equipment that
is not easily accessible and the process is unpleasant (claustrophobic and noisy),
these methods are not suitable for testing large groups of people due to cost and
time, neither mental disease patients’ for safety and discomfort reasons.
When it comes to cognitive methods, the tests based on problem solving
tasks and questions, in order to detect a cognitive impairment, are the most
commonly used by doctors. Cordell et al presents in [27] a comparative study of
these methods, including Mini-Cog test or Saint Louis University Mental Sta-
tus (SLUMS) [28]. Also it should be mentioned that the Mini Mental State
Examination (MMSE) is one of the most well-known and used tests [29]. Other
examples of cognitive tests not included in [27] are the memorization of in-
teracting objects in the Visual Association Test (VAT) [30] or the detection
of the prevalence of the right ear when sounds are memorized by Alzheimer’s
patients during the Dichotic Listening test [31]. The results provided by this
test demonstrate high accuracy and specificity. Nevertheless, the results show
a ceiling effect, since the test is not complex enough for high IQ patients [29].
Other non-invasive methods are focused on analysing visual impairments
since visuospatial functions and visual processes decline due to Alzheimer [32,
33]. These methods evaluate the mental state of a patient through the measure-
ment of the reaction time in certain stimulus, the assessment of attention or
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the evaluation of patients visual memory [33, 34]. Pereira, et al. [33] analysed
different methods that use eye-movement to determine visual impairments in
Alzheimer patients. These methods compared eye movements of healthy people
with Alzheimer patients in terms of fixation duration, refixations or saccade
orientation. As a result, most of the studies revealed an increment of saccades,
defects in fixations and slow pursuit movements. Nevertheless, as suggested by
Pereira et al in [33, 34], these studies fail to consider attentional impairments as
a multi-domain concept and their results still need to be corroborated by future
studies.
Recently, due to the new advances in computer technologies, Virtual En-
vironments (VEs) started to become part of medical tests and rehabilitation
therapies. The study conducted by Garc´ıa-Betances et al in [13] shows the ad-
vantages of virtual environments for Alzheimer’s disease and point out the lack
of immersion or interaction in most of the current virtual reality applications.
The work presented by Tarnanas, et al. in [11] demonstrates that the use of
VEs is beneficial, when it comes to early dementia detection. It is possible
to improve the results from previous cognitive tests, since it reduces the floor
and the ceiling effects, creating tests that adapt to the patients’ IQ; and it is
possible to increase immersion in the task that is in progress. Their work uses
large screens to display the environment and some depth sensors to recognize
the gestures of the patients’ body. This approach requires the patient to move
to the location where the facilities for this test are available, due to the fact
that the components are not portable and cost efficient making it inappropriate
for e-health applications.
Recently approaches were introduced to validate the use of virtual reality for
neurocognitive assessment. The work presented in [16] asses complex attention
on healthy and military subjects and examine the ecological validity of virtual
reality using head mounted VR devices in comparison with less immersive con-
ditions. In [35] the authors evaluate learning and memory cognitive abilities on
healthy controls while navigating through a virtual environment using a head
mounted VR device. The test is based on traditional neurocognitive methods
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proving the correlation between their and the traditional tests’ results. Cush-
man et al. in [36] also present a comparative study between a navigation system
on VEs and the real world while evaluating Alzheimer’s participants navigation
aptitudes and proving the ecological validity of VR environments. Parson et al
work in [14] analyse the appropriate way to create neurocognitive interfaces in
VEs. In this paper they consider the possible lost of the experimental control
related with the VE fidelity. An increase of the VE fidelity means a loss in the
control so a balance should be found in relation with the test type. Another
interesting concept is the physchophysiological computing; this term implies the
human monitoring by the computer being able to create user adaptive applica-
tions.
2.1. Relation with the proposed work
In our work a novel non-invasive Alzheimer’s detection screening test based
on VEs is proposed. The Virtual Environment created for this test is a room
that the patients can recognize and feel comfortable, such as a doctor’s office, a
living room, etc. The use of new immersive technologies, such as virtual reality
glasses, provides a huge improvement in immersing the subjects in a VE and its
combination with depth cameras makes possible the improvement of interaction
with the VE. The proposed and developed tool is the first Alzheimer’s detection
screening test that provides a full immersion in Virtual Environments implying
that the patients are able to be more focused on the tasks, while additional
information related to the environment-patient interaction is obtained. Also,
it is possible to adapt some of the tasks to the patient’s IQ level during the
test, avoiding the ceiling effect. The adaptability to the participant’s IQ is
based on user’s options election during the procedure and the test supervisor
criteria, therefore it is not related with the physchophysiological computing
concept presented in [14].
These test are based on the examination of cognitive abilities. Therefore,
the tests are question and task based, trying to provide a user friendly and
comfortable environment for the patients. Furthermore, the proposed tests do
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Figure 1: Virtual Reality glasses (Oculus Rift DK2 or Samsung Gear VR) and Depth sensor
(Microsoft Kinect 2) are the devices required to perform the tests.
not consider only memory tasks, but introduce novel approaches based on the
concept of differentiating between reality and a virtual world; and on a new
cognitive test that aims to identify normal and abnormal events or objects
present in the virtual scene. Also, novel checks are proposed based on a reversed
Turing test, where the patients’ cognition is evaluated according to their ability
in distinguishing absurd from correct information or a machine from a human.
3. Proposed Methods
The proposed methods for Alzheimer’s detection were developed to be con-
ducted in Virtual Environments. Thus, VR glasses are used in order to maximize
the patients’ immersion in the VE and a depth camera is utilised to track the
patients’ movements and animate their avatars in order to increase the interac-
tivity (see figure 1). These tools are affordable and they can be reused by other
patients, resulting to a low cost Alzheimers detection application. The main
scene was designed such as to recreate a doctor’s office or any other real room
that the patient can recognize (office, living room), see figure 2. Then, the tests
were designed taking advantage of the virtual environment versatility, such as
the absence of physical limits.
Regarding the real environment, since Alzheimer’s patients are mainly el-
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Figure 2: Virtual Reality Room. Corner and top down view
der people; all tasks are performed seated on a chair requiring only minimal
movements. The patient is sitting on a comfortable chair about 2 meters in
front of the depth sensor and is helped to place on the Virtual Reality glasses
(see figures 3 and 4). Once the patient feels comfortable with the glasses, we
proceed with the tests. The doctor (or test supervisor) has to be in front of the
computer locally or remotely, in order to control the software application and is
advised to take notes during the process typing details that may be useful later,
since it is possible to obtain in that way extra information about the patient’s
behaviour. Despite most of the tests are automatic and the patient only has
to follow the instructions, some actions, such as starting a new task or play-
ing sounds, requires the interaction of the doctor/instructor in order to provide
enough time to the patient to perform the actual tasks or to add a degree of
randomness and adaptability.
All the proposed tests should be performed under the supervision of a healthy
person following the instructions on the screen or the test’s information sheets.
Despite the fact that the test could be monitored by any person without mental
impairments, it is recommendable that the supervisor during the tests to be a
doctor, either locality or remotely, since additional information may be obtained
during the whole process. In this work, four tests are introduced: Virtual
Objects Memorization, Abnormal Objects Recognition, Virtual vs. Real Sounds
and Bot Doctor Turing Tests.
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(a) (b)
Figure 3: (a) Top down view showing the position of the devices, and the location of the
patient and the supervisor. Around the patient should be enough space to avoid collation
with any real objects. (b) Side view showing the position of the devices, and the location of
the patient and the supervisor. The depth sensor should be located approximately 1 meter
above the floor and the patient has to be approximately 2 meters away from the depth sensor,
in order to be in the view range.
Figure 4: Early detection Test setup. The patient is sat in front of the depth sensor, wear-
ing the VR glasses. The supervisor/doctor monitors the test from the computer locally or
remotely.
3.1. Virtual Objects Memorization test (VOM)
VOM is a test focused on memory and its main objective is the analysis of
patients learning and memory cognitive domain [17]. It is split into three steps.
The first step of this memory test is the recognition of six different virtual
objects. The objects are commonly used during everyday activities making
them easily identified and recognized. The objective of this first task is to check
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Figure 5: Virtual Object Memorization tasks. Object Recognition task where the patient has
to identify and select the correct name of the objects on a table.
if the patient has problems in recognizing quotidian objects (see figure 5). Once
all the objects are recognized, a virtual monitor displays all of them in specific
positions (the positions of these objects are the ones where they normally are
located on a desk). Therefore, the patient is asked to memorize the objects but
nothing is mentioned about their position.
During the second step, the subject is asked about the objects’ locations, in
order to check the visual and the associative memory of the patient. In more
details, the desk is shown in front of the patient and a number appears in the
position where an object was located, while a list of the six possible objects
is provided (see figure 6). The subjects are asked about the object that was
located in the position indicated by a number and they have to select the name
of the correct one. The fact that the objects were located in logical positions
should help the user to select the right answers.
Finally, in the last task, interacting objects are placed in the virtual room
and have to be located and memorized by the patient. Then, one of the objects is
shown and the subject has to recall its interacting couple and their functionality.
Once the third stage is completed, there is an extra task associated with the first
step, where the patient is asked to recall the objects that were shown. The aim of
the last two tasks is to evaluate the patient’s short-term memory incorporating
interacting objects and their functionalities. So, the novel part here is focused
12
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(a) (b)
(c)
Figure 6: Virtual Object Memorization tasks. (a) The objects in their respective location are
shown in order to be memorised by the patient. (b) Objects’ location task where the patient
has to select the name of the object that was shown on the screen. (c) A close view of the
objects and their locations.
mainly on the combination of interacting objects with their functionalities.
Also, it should be mentioned that in order to proceed through the test, the
subject has to select amongst different options. This selection is performed
moving the head to aim towards the desired option using the direction of view
(scope), as we can see in Figures 5 and 6. Therefore, the patients have to move
slightly their head to fulfil the tasks.
This test if all tasks are completed successfully provides in total 21 points.
The points are associated with the recognition of the objects, the recall of their
position and the recall of the objects themselves and their functionality.
3.2. Abnormal Objects Recognition test (AOR)
AOR is a test that evaluates if the patient is able to discern if something
is abnormal or not within the virtual environment and it is divided into three
13
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Figure 7: Abnormal Objects Recognition test preview. Some abnormalities such as the upside-
down pot and the toy car going through the mirror can be observed in this figure.
Table 1: Abnormalities in the room ordered by identification difficulty
Object Abnormality
Chair Wanders around the room
Mug Spins
Car Goes through the wall
Change shape when goes through the mirror
Potted plant Upside down
Mirror Does not reflect
separate stages. During the first stage, the patient is asked to detect any abnor-
malities present in the room in order to analyse their perceptual-motor cognitive
skills [17]. Table 1 describes the abnormalities that can be find in the room.
The subject in the second stage is requested to read the clock that is located
on one of the walls in the room. Shortly afterwards the patient is asked if the
illumination (i.e. ambient light) of the room is in accordance with the time, (see
Figure 7).
Finally, the objective of the third stage is to evaluate the coordination of the
patient when the physics of a mirror reflection are changed. An avatar, whose
movements are linked to the patients movements, is displayed in front of them.
Therefore, it will look like a mirror; however, the movements of the avatar are
14
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Table 2: Movements that the patient has to perform to move the avatar and their evaluation
Task Answer and Evaluation
Raise your right hand.
Is the avatar behaving as a mirror? No = 1 point
Move the body of the avatar towards the mug
(there is a mug on the right of the avatar) First attempt = 1 point
Grab the mug First attempt = 1 point
Figure 8: Virtual vs Real Sounds test preview. Some of the visual clues such as the fly, the
clock and the mobile phone appear on this figure.
reversed. Once the patients detect how the avatar moves, they are asked to
perform specific movements with the avatar (see table 2). This task allows the
study of perceptual-motor and executive function impairment [17].
This test can provide a maximum of 10 points. Seven points are associated
with the correct detection of the abnormalities and three are associated with
the correct movement of the avatar.
3.3. Virtual vs Real Sounds test (VRS)
The main objective of VRS test is the detection and recognition of ob-
jects/events through audio and to check if the patient is able to discern between
real and virtual sounds. As a result this test analyses patients’ mental and
cognitive flexibility [17].
Different sounds are played during the test, such as a clock ticking, a fly,
15
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Figure 9: Selection Based - Bot Doctor Turing Test preview. The two avatars represent a
doctor. The closest one is the one asking the questions in the screen, once it finishes the
other avatar will move to the position of this avatar and ask it will ask its questions. The
participant has to read the information above and choose one of the options below moving
the scope over the desired choice using head movements.
rain at the background, etc., (see Figure 8). The patient has to recognise and
name all the sounds that they listen during the test. In addition, the virtual
environment will provide some visual clues to help them with the identification.
Once the subjects have identified all the sounds, they are asked about the origin
of the sounds. During this stage, the source of some sounds is coming either
from the virtual environment or the real world reproduced by the supervisor.
This second part requires the patient to recall all the sounds that were played
and to identify which ones were reproduced by the supervisor. This test gives
a maximum score of 6 points. One point is obtained for each object that is
recognized and categorized properly as real or virtual.
3.4. Bot-Doctor Turing Test (BDTT)
The proposed Turing test is based on the ability of a patient to evaluate if a
computer is able to impersonate a human. In order to perform the test, a human
and a computer are located in a room, while the patient is in another location
trying to communicate with the human and the computer in the first room
without knowing who is responding, (see Figure 9). The patient in the second
room asks questions aiming to distinguish who is the human and who is the
16
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computer [18]. We propose two different versions of the Alzheimer Turing test
to evaluate patients’ executive function, such as the ability to hold information
and manipulate it and assess their process of making decisions [17].
3.4.1. Selection Based - Bot-Doctor Turing Test
In this test two virtual doctors have been designed to provide answers about a
specific topic to the patient based on a simple AI architecture. The conversation
is formatted using a tree structure and is based on the same discussion and
interaction system used in classic adventure video games. In more details, the
discussion system provides a set of questions to the patients and based on their
choice the AI-Bot-Doctors will provide an answer. The patient is informed that
will have two discussions with two different Bot-Doctors and each AI system
provides related but different answers. One of them will provide logical and
correct answers, whereas the other will provide incorrect and sometimes absurd
responses.
The whole discussion takes place in a virtual room, and two different human
like avatars are used for the Bot-Doctors. The patients are immersed using
the virtual reality glasses in the Virtual Environment, allowing them to see the
avatars of the virtual doctors. Different variations of this test can be designed
depending on the avatars used to represent the AI-Bots. In more details the
Doctors’ avatar can have either human or robotic appearance. Therefore, there
can be 2 human avatars, 2 robotic avatars or a mixture of them. The objective
of using non-human-like avatars is to check if the patient will have a different
interaction if the avatar that provides the information does not look as a human.
So, with this approach we can evaluate if the visual characteristics of the avatars
can affect the provided answers. The test terminates either when the patients
decide that they have asked enough questions to the avatars or if all the provided
questions have been answered. This test gives in total 3 points. One point if the
answer is that both doctors provided real answers and three if they distinguish
them correctly.
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3.4.2. Script Based Bot-Doctor Turing Test
The second Alzheimer Turing test that is suggested is script based using
chatbots. Chatbots are defined as computer programs that can maintain a
conversation with a person [37]. ELIZA, IBM’s Watson and Apple’s Siri are
some of the most famous chatbots. ELIZA was the first chatbot and was created
by Joseph Weizenbaum; IBM’s Watson is a chatbot that won in Jeopardy TV
show in 2011; and Apple’s Siri is the iPhone’s personal assistant application.
Also, many open source chatbots are available such as ALICE that can be used
in this Bot-Doctor Turing test.
In order to interact with chatbots, people start a chat with the AI, they write
the messages on the computer chat screen and the AI or human will engage in
conversation. If voice recognition and synthesis are supported then this option
can be selected. The proposed test uses a chatbot (e.g. ALICE) and a human to
have a discussion with the patient. Therefore, all the entities that are involved
in this test are the same as the used in a Turing Test, two humans and one
computer. The patients are asked to chat for five minutes with each entity and,
at the end, they are asked to decide which entity is a human. The intelligence of
the chatbot is settled in accordance with patient’s IQ in order to avoid the ceiling
effect. It is expected that Alzheimer’s patients fail distinguishing a simple AI
based chatbot from a human. Regarding the scoring system, this test provides
exactly the same points as the previous one.
4. Results
4.1. Participants
The 20 participants of this test are aged between 23 and 82 year old including
both healthy people and Alzheimer’s patients diagnosed with mild dementia less
than year ago. Furthermore, Alzheimer’s patients in advanced conditions were
tested but, the process was not possible to be completed. Half the subjects were
male and the other half female of whom eleven had college or higher educational
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background and nine did not reach high school. None of the Alzheimer’s par-
ticipants’ education level reached high school. The participants’ nationalities
included French, Spanish, Vietnamese and Greek so the non English speakers
were tested in their own language. It has to be mentioned that one of the
patients was illiterate so the test was performed orally.
4.2. Data
The main data collected during the experiment are the individual scores for
each test. As it was explained in section 3, each test has a maximum score
and each task provides a different number of points. In more details, regarding
the recognition and memory tasks, each recalled and recognized object scores 1
point.
In addition, patients have been also tested using other well-known state of
the art Alzheimer screening tests, in order to perform a comparative study and
allow the evaluation of the proposed novel non-invasive diagnosis screening tests.
All the tests were computerized so the patients have to use a computer through
the whole process retaining also the same conditions among all tests. The state-
of-the-art screening tests used in our comparative study are Dr. Oz Memory
Quiz [28]; Visual Association Test [30]; and Dichotic Listening Test (DLT)[31].
The Dr. Oz Memory Quiz is an alzheimer detection screening method, that
is based on SLUMS test [28]. It is formed by 17 questions and tasks that score
1 point each.
In the case of Visual Association Test (VAT) [30], six pairs of objects are
shown consecutively, and after the patients memorize them, one object of each
pair is shown and they have to recall its couple. This test gives a maximum
score of 6 points, one per recalled couple.
During the Dichotic Listening Test (DLT), the patients have to memorise 6
digits played to each ear separately and the process is repeated 8 times [31]. As
the results are stored by ear, the maximum score is 24 points per ear. This test
is based on the fact that the difference of the recalled digits between the left and
right ear in a healthy person is minimal compared with the predominance of
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the right ear for patients with Alzheimer’s. Therefore, the data collected from
this test is the difference of the left ear score minus the right ear score. The
maximum score for each ear (24) is added in order to obtain positive values.
Finally, the maximum possible value is delimited to 24, since left predominance
or both ear equivalence are considered as healthy results (DLTre - Dichotic
Listening Test right ear). In this way, the results decrease when the right ear
predominance is high. In this way, these results and the ones obtained by the
other tests can be compared. In addition, the number of digits recalled are also
collected. This value will represent the memorization capacity.
4.3. Evaluation
The mean results for each test in relation to the subject’s health status are
shown in Table 3. It is observed that healthy patients have achieved results close
to the maximum score of each test. For example, the normalised averaged score
of the Abnormal Objects Recognition test, for healthy subjects, is 0.826316,
which is close to the maximum score of 1. On the other hand, the Alzheimer’s
patients have obtained significantly lower scores in comparison with the healthy
participants. For instance, healthy subjects have obtained a mean of 0.924821,
whereas the Alzheimer’s subjects scored 0.238100 in the Virtual Objects Memo-
rization test. This separation between results is also apparent in the other state
of the art tests, such as the relation 0.986842-0.375000 (Healthy Alzheimer)
on the Dichotic Listening test (DLTre). Table 4 demonstrates that the p-value
of the novel tests proves that their results are correlated with the healthy and
Alzheimer’s status of the patients. When it comes to sensitivity and specificity
in relation to the detection of healthy patients, the results are perfect. This
suggest that more subjects need to be tested in order to corroborate the results
of the novel Alzheimer’s screening tests.
Figure 10 compares the worst healthy participant results and the best Alzheimer’s
participant ones. There is a clear difference in the results that allows to sepa-
rate Alzheimer’s from healthy participants. For example, the current state of
BDTT’s score system relies on few marks (3 points) so even if the given marks
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Figure 10: Worst healthy control result vs. best Alzheimer’s result comparison. The scores of
each test are show as percentages where the 100% correspond to the maximum result possible
of each test.
Table 3: Normalised mean value of the tests regarding the Healthy and Alzheimer’s patients
Age DrOz VAT DLT DLTre
Healthy 42.47 .900953 .894732 .889253 .986842
Alzheimer 78.00 .529400 .000000 .437500 .375000
Age VOM AOR VRS BDTT
Healthy 42.47 .924821 .826316 .833311 .736832
Alzheimer 78.00 .238100 .200000 .333300 .385600
are based on a strong criteria, the addition of new ones will allow to increase
the robustness of the test.
Table 4 also demonstrates that most of the results of the test are not corre-
lated with the age and the educational level of the patients, since the p-values
do not reject the Null hypothesis. Regarding the novel test AOR results a
p-value of 0.003 (age) and 0.004 (educational level), indicating a relationship
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Table 4: T-test for each test according to the healthy and Alzheimer’s cases. The p-value
(Sig. (2-tailed)) is less than 0.01 so the Null Hypothesis is rejected
Sig.(2-tailed)
Dementia Age Educational Gender
Level
DrOz e.v.aa .000 .033 .067 1.000
e.v.n.ab . .088 .104 1.000
VAT e.v.a .001 .325 .462 .615
e.v.n.a . .395 .492 .615
DLT e.v.a .000 .038 .111 .616
e.v.n.a . .076 .142 .619
DLTre e.v.a .000 .198 .262 .400
e.v.n.a . .314 .326 .410
VOM e.v.a .000 .052 .045 .908
e.v.n.a . .128 .084 .909
AOR e.v.a .000 .003 .004 .433
e.v.n.a . .020 .013 .435
VRS e.v.a .000 .061 .078 .818
e.v.n.a . .113 .104 .818
BDTT e.v.a .000 .131 .041 .438
e.v.n.a . .178 .060 .445
aEqual Variances Assumed
bEqual Variances Not Assumed
with those factors. Therefore, tasks that are more difficult can be added for pa-
tients with high educational background in order to eliminate this correlation.
When it comes to the relationship between the results and the gender of the
participants, the results of the male participants and the females one are not
correlated (see table 4).
The correlation between the DrOz, VAT and DLT tests, and the novel ones
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Table 5: Correlation between state of the art tests and novel ones
DrOz VAT DLT DLTre
VOM Pearsons correlation .589** .666** .741** .832**
Sig. (2-tailed) .006 .001 .000 .000
AOR Pearsons correlation .676** .526* .723** .724**
Sig. (2-tailed) .001 .017 .000 .000
VRS Pearsons correlation .486* .602** .720** .688**
Sig. (2-tailed) .030 .005 .000 .001
BDTT Pearsons correlation .388 -.060 .228 .249
Sig. (2-tailed) .100 .807 .347 .304
**Correlation is significant at the 0.01 level (2-tailed)
*Correlation is significant at the 0.05 level (2-tailed)
is shown in Table 5, where the Spearman’s correlation has been calculated,
including the correlation coefficient and the p-value. Most of the novel tests
result high correlation value with at least two of the previous tests.
In addition to the numerical results, some notes were collected during the
testing process that could be used by the doctors to make a decision. The most
interesting of these notes is the lack of attention of Alzheimer’s patients due
to the animated virtual environment. For example, during VOM test there are
some animated objects close to the questions area that divert the attention of
the patients making them to forget about the task in progress. This reveals a
problem in the Complex Attention cognitive domain.
4.4. Qualitative evaluation of the proposed system
At the end of the process, patients were asked to evaluate the application.
They had to fill a form evaluating the quality of the application in terms of inter-
action; simplicity of instructions/processes and the comfort of the VR glasses.
Additionally, the patients had the option to write any additional comments
about the proposed cognitive tests.
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Table 6: Qualitative evaluation of the proposed cognitive tests by the participants. Four
characteristics were evaluated from 0 (Very bad) to 5 (Very good)
Type Mouse Inter Kinect Inter Instructions VR Glasses
>= 50 4.17(0.983) 4.00(1.155) 4.43(0.787) 3.86(0.9)
< 50 4.33(0.778) 3.33(0.985) 4.17(0.835) 3.50(1.0)
The average evaluation of the proposed approach was positive. Some of the
subjects commented that the glasses were not comfortable at the end of the
test and that the graphics could be improved, which is something that will be
available in future versions of the hardware devices. Nevertheless, most of the
participants evaluated the application as motivating and interesting; and the
interaction and instructions as simple and easy to understand.
Table 6 shows the overall evaluation of the proposed cognitive tests provided
by the participants. The interaction with the application (i.e. keyboard, mouse,
depth sensor and virtual reality glasses), the quality of the instructions (i.e.
written and/or oral provided by the supervisor) and the comfort of the VR
glasses were evaluated from 0 (really bad) to 5 points (really good). The overall
evaluation obtained is positive, since the average result in all these categories is
above 3 points, with elder people being more enthusiastic with new technologies,
probably due to the completely new to them features and capabilities.
5. Conclusion
Alzheimer is a disease without foreseen cure, that is affecting more people
every year, with the related research and associated services (care) cost to in-
crease rapidly. Our objective is to provide affordable approaches that would
help improving the current cognitive based detection systems.
Virtual Environments (VEs) start to be part of medical treatments or diag-
nosis methods, and they have been proved to be considerably useful by applying
cognitive tests in secure and controlled environments; helping to increase the
effectiveness of the related methodologies. These facts have been further vali-
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dated with the proposed novel tests, since the results obtained show that it is
possible to create an accurate e-health screening Alzheimer’s diagnostic system.
In this work, new methods for detection of Alzheimer’s disease based on Virtual
Environments were introduced. The proposed tests are focused on the evalua-
tion of memory loss related to common objects, recent events, the diagnosis of
problems in expressing and understanding language and the ability to recognise
abnormalities, and to differentiate between virtual worlds and reality. In addi-
tion, two novel tests related with Alan Turin Imitation Game were proposed,
where the human’s intelligence is evaluated instead of the machine’s one. The
proposed approaches were evaluated in a comparative study with well-known
state-of-the-art cognitive tests. Finally, the obtained results indicate that the
proposed methodologies and tests can provide accurate indications of the pres-
ence of Alzheimer and the potential to further improve them by providing tests
more adaptive to the patients.
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HIGHLIGHTS
• Computerized cognitive tests for early detection of Alzheimer’s using Vir-
tual Environments
• Virtual Reality devices for adaptive cognitive tests
• Computerized cognitive test that incorporates a reverse version of Turing
Test
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